Cargando…

Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein

BACKGROUND: Plants remain an important source of new drugs, new leads and new chemical entities. Triptolide is a diterpenoid epoxide isolated from Tripterygium wilfordii Hook F that possesses a broad range of bioactivities, including anti-inflammatory, immunosuppressive and anti-tumor properties. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Zhitao, Chen, Xulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205289/
https://www.ncbi.nlm.nih.gov/pubmed/25323821
http://dx.doi.org/10.1186/s12977-014-0088-6
_version_ 1782340674547351552
author Wan, Zhitao
Chen, Xulin
author_facet Wan, Zhitao
Chen, Xulin
author_sort Wan, Zhitao
collection PubMed
description BACKGROUND: Plants remain an important source of new drugs, new leads and new chemical entities. Triptolide is a diterpenoid epoxide isolated from Tripterygium wilfordii Hook F that possesses a broad range of bioactivities, including anti-inflammatory, immunosuppressive and anti-tumor properties. The antiviral activity of triptolide against human immunodeficiency virus type 1 (HIV-1) has not been reported. RESULTS: In this study, nanomolar concentrations of triptolide were shown to potently inhibit HIV-1 replication in vitro. To identify the step(s) of the HIV-1 replication cycle affected by triptolide, time-of-addition studies, PCR analysis and direct transfection of viral genomic DNA were performed. The results of these experiments indicated that triptolide acts at the stage of viral gene transcription. In addition, a luciferase-based reporter assay that allows quantitative analysis of long terminal repeat (LTR)-driven transcription showed that Tat-induced LTR activation was impaired in the presence of triptolide. Moreover, Western blot analysis of exogenous gene expression (driven by the human elongation factor 1 α subunit promoter) in transiently transfected cells revealed that triptolide specifically reduces the steady-state level of Tat protein, without suppressing global gene expression. Further studies showed that triptolide accelerates Tat protein degradation, which can be rescued by administration of the proteasome inhibitor MG132. Mutation analysis revealed that N-terminal domains of Tat protein and nuclear localization are required for triptolide to reduce steady-state level of Tat. CONCLUSION: This study suggests for the first time that triptolide exerts its anti-HIV-1 activity by specifically prompting the degradation of the virally encoded Tat protein, which is a novel mechanism of action for an anti-HIV-1 compound. This compound may serve as a starting point for developing a novel HIV-1 therapeutic approach or as a basic research tool for interrogating events during viral replication.
format Online
Article
Text
id pubmed-4205289
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42052892014-10-23 Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein Wan, Zhitao Chen, Xulin Retrovirology Research BACKGROUND: Plants remain an important source of new drugs, new leads and new chemical entities. Triptolide is a diterpenoid epoxide isolated from Tripterygium wilfordii Hook F that possesses a broad range of bioactivities, including anti-inflammatory, immunosuppressive and anti-tumor properties. The antiviral activity of triptolide against human immunodeficiency virus type 1 (HIV-1) has not been reported. RESULTS: In this study, nanomolar concentrations of triptolide were shown to potently inhibit HIV-1 replication in vitro. To identify the step(s) of the HIV-1 replication cycle affected by triptolide, time-of-addition studies, PCR analysis and direct transfection of viral genomic DNA were performed. The results of these experiments indicated that triptolide acts at the stage of viral gene transcription. In addition, a luciferase-based reporter assay that allows quantitative analysis of long terminal repeat (LTR)-driven transcription showed that Tat-induced LTR activation was impaired in the presence of triptolide. Moreover, Western blot analysis of exogenous gene expression (driven by the human elongation factor 1 α subunit promoter) in transiently transfected cells revealed that triptolide specifically reduces the steady-state level of Tat protein, without suppressing global gene expression. Further studies showed that triptolide accelerates Tat protein degradation, which can be rescued by administration of the proteasome inhibitor MG132. Mutation analysis revealed that N-terminal domains of Tat protein and nuclear localization are required for triptolide to reduce steady-state level of Tat. CONCLUSION: This study suggests for the first time that triptolide exerts its anti-HIV-1 activity by specifically prompting the degradation of the virally encoded Tat protein, which is a novel mechanism of action for an anti-HIV-1 compound. This compound may serve as a starting point for developing a novel HIV-1 therapeutic approach or as a basic research tool for interrogating events during viral replication. BioMed Central 2014-10-17 /pmc/articles/PMC4205289/ /pubmed/25323821 http://dx.doi.org/10.1186/s12977-014-0088-6 Text en © Wan and Chen; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wan, Zhitao
Chen, Xulin
Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein
title Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein
title_full Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein
title_fullStr Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein
title_full_unstemmed Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein
title_short Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein
title_sort triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of tat protein
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205289/
https://www.ncbi.nlm.nih.gov/pubmed/25323821
http://dx.doi.org/10.1186/s12977-014-0088-6
work_keys_str_mv AT wanzhitao triptolideinhibitshumanimmunodeficiencyvirustype1replicationbypromotingproteasomaldegradationoftatprotein
AT chenxulin triptolideinhibitshumanimmunodeficiencyvirustype1replicationbypromotingproteasomaldegradationoftatprotein